Biosimilars market expcted to expand with health care reform

According to Pharma Live, by 2017, the biosimilars sector will reach $10 billion dollars. While healthcare reform is expected to hit the biotech sector in one way, the reform will allow them access to more patients in the United States, as well as rewarding biotechs for innovating and focusing on biosimilars.

Next week, we are hosting the Business of Biosimilars conference in Boston, MA. The event will delivers effective strategies to navigate scientific, regulatory, economic, and legal challenges you face to remain competitive in commercializing your biosimilar portfolio in the United States and abroad. We hope to see you in Boston!

Share this article with your social network, just click below to share now!

Share |